---
document_datetime: 2024-11-25 15:23:52
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/senshio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: senshio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 8.8819084
conversion_datetime: 2025-12-27 14:43:13.276253
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Senshio

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                     |
|----------------------|----------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10340 /202402  | Periodic Safety Update EU Single assessment - ospemifene | 03/10/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                           |
| R/0048               | Renewal of the marketing authorisation.                  | 25/07/2024                          | 01/10/2024                                  | SmPC, Labelling and PL           | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Senshio in the approved indication remains favourable and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                                  | therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------|
| IB/0047     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                           | 31/05/2024 | n/a        |                                  |                                                                                             |
| IB/0046/G   | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 30/08/2023 | n/a        |                                  |                                                                                             |
| IA/0045     | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                           | 06/06/2023 | n/a        |                                  |                                                                                             |
| IAIN/0044/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                              | 07/03/2023 | 16/02/2024 | SmPC, Annex II, Labelling and PL |                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                       |                                                                    |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------|
| IA/0043   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                          | 31/01/2023 | n/a        |                       |                                                                    |
| II/0042/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported                                                                                                               | 19/05/2022 | n/a        |                       |                                                                    |
| II/0041   | Extension of indication by lifting the second line treatment restriction. This is supported by the submission of the final study report of the imposed non-interventional post-authorisation safety study. As mentioned in Annex IID, this is an observational retrospective cohort study of ospemifene to assess the incidence of venous thromboembolism and other safety concerns as agreed in the Risk Management Plan (RMP), in vulvar and vaginal atrophy (VVA) patients treated with ospemifene compared to 1) patients newly prescribed SERMs for oestrogen- | 27/01/2022 | 24/02/2022 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Senshio-H-C-002780- II-0041 |

<div style=\"page-break-after: always\"></div>

|                     | deficiency conditions or breast cancer prevention, and 2) the incidence in untreated VVA patients. As a consequence, section 4.1 of the SmPC is updated. The Package Leaflet and Annex IID are updated in accordance. Version 2 of the RMP has also been submitted. In addition, the Marketing authorisation holder took the opportunity to update the list of local representatives in the Package Leaflet. The variation leads to amendments to the Summary of Product Characteristics, Annex II D and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                 |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10340 /202102 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/09/2021 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0039             | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/05/2021 | n/a        |                 |                                   |
| IA/0038             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/03/2021 | 24/02/2022 | Annex II and PL |                                   |
| IA/0037             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/12/2020 | 23/07/2021 | Annex II and PL |                                   |
| IAIN/0036/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 07/10/2020 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                             |            |            |                 |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10340 /202002 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                                                                                                                                                                                                                                            | 01/10/2020 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0035/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                        | 24/07/2020 | n/a        |                 |                                   |
| IAIN/0033/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.b - Replacement or addition of a | 18/03/2020 | 23/07/2021 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------|
| IA/0032/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 21/01/2020 | n/a        |             |                                                                                                                        |
| PSUSA/10340 /201902 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/09/2019 | 22/11/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<div style=\"page-break-after: always\"></div>

|        |                                         |            |            |                                  | PSUSA/00010340/201902                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------|-----------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0028 | Renewal of the marketing authorisation. | 25/07/2019 | 21/10/2019 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Senshio in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds: There is an imposed category 1 Post Authorisation Safety Study (PASS) ongoing. This study evaluates the risk of various side effects in a cohort of post-menopausal women newly prescribed ospemifene relative to 1) a cohort of patients diagnosed but not treated for vulvar and vaginal atrophy and 2) a cohort of postmenopausal women newly prescribed other SERM therapies utilised for oestrogen- deficiency conditions or breast cancer prevention. The primary objective of the study is to compare the incidence of venous thromboembolic events in a real-world patient population. Secondary objectives includes e.g. assessment of off label use among ospemifene patients in the EU. The MAH is obliged to submit yearly interim reports for this 5- year study. The estimated date of submission of final report is 31 March 2021. Currently, the third PASS annual report (dated 26 October 2018) has been submitted and assessed. However, the comparative analysis cannot be completed until the target sample size has been achieved. The final results of this study may yield important safety data that could have impact on the benefit-risk balance of the product. Therefore, a recommendation for a second renewal of the marketing authorisation based on pharmacovigilance grounds is warranted. |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                            |            |            |                        | Therefore, based upon the safety profile of Senshio, which requires the submission of 1-yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years' time.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0031             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 05/09/2019 | n/a        |                        |                                                                                                                                                                                                            |
| IA/0030             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 08/08/2019 | n/a        |                        |                                                                                                                                                                                                            |
| IA/0027             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                              | 21/03/2019 | n/a        |                        |                                                                                                                                                                                                            |
| T/0026              | Transfer of Marketing Authorisation                                                                                                                                        | 18/01/2019 | 11/03/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                            |
| IB/0024             | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                | 28/09/2018 | n/a        |                        |                                                                                                                                                                                                            |
| IAIN/0025           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                         | 21/09/2018 | n/a        |                        |                                                                                                                                                                                                            |
| PSUSA/10340 /201802 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                   | 06/09/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0023             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                   | 23/07/2018   | 11/03/2019   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10340 /201708 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                                                                                                                                                                                    | 22/03/2018   | 28/05/2018   |                          | The MAH conducted a review of headache cases and identified 167 individual case safety reports, of which there were reports of headache (n=147), migraine (n=15), sinus headache (n=2) and single reports for head discomfort, migraine with aura and exertional headache. There were 11 cases that included a positive dechallenge, with 5 of the cases also showing a positive rechallenge. A strong temporal relationship between ospemifene and headache was seen in many of the cases, which suggests a causal relationship between ospemifene and headache. The MAH has proposed to update Section 4.8 of the Summary of Product Characteristics and Section 4 of the Patient Information Leaflet to include headache as an adverse event for ospemifene, with a frequency of common which |
| IB/0020/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation | 10/01/2018   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0019/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                          | 12/10/2017   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                |            |            |                     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------------------|
| PSUSA/10340 /201702 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/09/2017 | n/a        |                     | PRAC Recommendation - maintenance |
| IAIN/0018/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 13/09/2017 | 19/02/2018 | Annex II and PL     |                                   |
| IA/0017             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                  | 18/07/2017 | n/a        |                     |                                   |
| IB/0015             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                                                                                                                                                                                              | 27/04/2017 | 19/02/2018 | SmPC, Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|                     | tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10340 /201608 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/03/2017 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0010             | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 02/03/2017 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0012/G           | This was an application for a group of variations. - Update of section 4.5 of the SmPC in relation to CYP3A4 based on the results of study E1508I0242and in fulfilment of PAM 008. - Update of section 5.2 of the SmPC with information on ospemifene metabolism and excretion based on the results of study E1508I0242 in fulfilment of PAM 013 and PAM 014. - Update of section 5.2 of the SmPC with information on ospemifene distribution based on the results of studies OSP-PF-046-N and OSP-PF-047-N in fulfilment of PAM 006 and PAM 007. - Update of section 5.2 of the SmPC based on the results of the bile salt export pump (BSEP) transporter study OSP-PF-041-N in fulfilment of PAM 009. As a consequence, an updated RMP version 1.2 is provided accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 02/02/2017 | 19/02/2018 | SmPC | Drug interaction studies were performed with probe substrates for CYP2C9 (warfarin), CYP3A4 (midazolam), CYP2C19, and CYP3A4 (omeprazole) and CYP2B6 (bupropion). Ospemifene did not cause a clinically meaningful change in the exposure to the substrates, indicating that ospemifene does not affect those enzyme activities in vivo to a clinically significant extent. Ospemifene and 4-hydroxyospemifene are highly (both >99%) bound to serum proteins. Plasma/blood cell partitioning of [14C]-Ospemifene (<3%) and [14C]-4- hydroxyospemifene (<2%) is low. The apparent volume of distribution is 448 l. In in vitro studies, ospemifene and 4 hydroxyospemifene did not inhibit bile salt export pump (BSEP) transporters at clinically relevant concentrations. Following oral administration of [3-H]-ospemifene in the fasted state, approximately 75% and 7% of the dose was excreted in faeces and urine respectively. Less than 0.2% of the ospemifene dose was excreted unchanged in urine. Following a single oral administration of 60 mg ospemifene in the fed state, 17.9%, 10.0% and 1.4% of the |

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |      | administered dose was excreted in faeces as ospemifene, 4-hydroxyospemifene and 4'-hydroxyospemifene, respectively. The fate of remaining fraction is unknown but can probably be explained by formation of glucuronide metabolites.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10340 /201602 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                                                                                                                                                                                                                                                             | 29/09/2016 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                      |
| IB/0013             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                       | 22/09/2016 | n/a        |      |                                                                                                                                                                                                                                        |
| IAIN/0011           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                   | 24/06/2016 | n/a        |      |                                                                                                                                                                                                                                        |
| IB/0008             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                            | 16/06/2016 | 13/02/2017 | SmPC |                                                                                                                                                                                                                                        |
| PSUSA/10340 /201508 | Periodic Safety Update EU Single assessment - ospemifene                                                                                                                                                                                                                                                                                                                                                             | 17/03/2016 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                      |
| II/0004             | Update of sections 4.5 and 5.2 of the SmPC as a consequence to new preclinical data submitted to fulfil the post-authorisation measures PAM 010 and                                                                                                                                                                                                                                                                  | 17/03/2016 | 13/02/2017 | SmPC | Glucuronidation is an important metabolic pathway in Humans. UGT1A3, UGT2B7, and UGT1A1 are the responsible enzymes for glucuronidation of ospemifene and                                                                              |

<div style=\"page-break-after: always\"></div>

|           | 011. In addition, the MAH took the opportunity to make minor corrections and to implement minor editorial changes in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | UGT1A8, UGT2B7, and UGT1A1 are the responsible enzymes for glucuronidation of M-1. The contribution of each isozyme is concentration dependent. Inhibition of UGT1A3, UGT2B7, UGT1A1, or UGT1A8 may potentially affect the glucuronidation of ospemifene and/or 4- hydroxyospemifene. Ospemifene and its major metabolite M-1 both are direct inhibitors of the human UGT enzymes UGT1A3, and UGT1A9 at clinically relevant concentration. Further also UGT1A4, UGT1A6, UGT2B7, and UGT2B15 are affected. The pharmacokinetics of drugs that are mainly metabolised by UGT1A3 and UGT1A9 could be affected when administered concomitantly with ospemifene and co-administration should be made with caution.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0005 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                    | 21/10/2015 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0002   | B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                             | 24/09/2015 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0003/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.b - Change in the batch size (including batch     | 10/09/2015 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| size ranges) of the finished product - Downscaling   |
|------------------------------------------------------|
| down to 10-fold                                      |